olfactory receptor family 7 subfamily E member 35 pseudogeneGenealiases: OR7E120 · OST018
Q-omics provides the consensus-scored OR7E35P profile across patient tissues and cancer cell-line models. OR7E35P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, OR7E35P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, OR7E35P RNA expression shows 6,374 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, BRCA, and STAD as cancer lineages where OR7E35P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E35P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E35P survival associations across molecular data types. OR7E35P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E35P RNA expression–survival associations across cancer types. High OR7E35P expression shows unfavorable associations in BRCA, UCEC and COAD, but favorable associations in LUSC, HNSC and ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for OR7E35P RNA expression.
This table summarizes OR7E35P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E35P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E35P shows lower tumor expression in BRCA, COAD and THCA and higher tumor expression in THCA. The BRCA box plot shows higher OR7E35P RNA expression in normal versus tumor tissue (log2 FC = −0.059, t-test p < 0.001).
This table shows molecular features associated with OR7E35P in patient tissues and cancer cell lines. In patient samples, OR7E35P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
